UCLA Integrated Staging System (UISS) Calculator for RCC
Projected 5-year survival: –
Localized / metastatic status: –
Risk level: –
The UCLA Integrated Staging System (UISS) is a clinical prognostic model used to predict the survival of patients with Renal Cell Carcinoma (RCC). While the standard TNM (Tumor, Node, Metastasis) system provides a baseline for staging, the UISS improves accuracy by integrating surgical staging with a patient’s functional status and the microscopic characteristics of the tumor.
Developed by researchers at the University of California, Los Angeles, it remains one of the most widely used tools for risk-stratifying RCC patients after surgery.
1. The Core Components of UISS
The UISS is unique because it combines three distinct data points to create a comprehensive risk profile:
- TNM Stage: The traditional anatomical extent of the tumor.
- Fuhrman Grade: A pathological grading system (1–4) based on the microscopic appearance of cancer cells (nuclear size and shape).
- ECOG Performance Status (PS): A clinical scale (0–4) used to assess a patient’s level of functioning in terms of self-care and physical activity.
2. Risk Stratification Models
The UISS categorizes patients into three risk groups: Low, Intermediate, and High. Because the prognosis for localized disease differs significantly from metastatic disease, the system provides two separate models.
A. Non-Metastatic (N0M0) Patients
For patients where the cancer has not spread, the UISS predicts the 5-year disease-specific survival (DSS):
| Risk Group | Clinical/Pathological Profile | 5-Year Survival (%) |
| Low | T1, Low Grade (1-2), ECOG 0 | ~92% |
| Intermediate | T1-T2, High Grade OR T3, Low Grade, ECOG 0 | ~67% |
| High | T3, High Grade OR T4, Any Grade, Any ECOG | ~44% |
B. Metastatic (M1) Patients
For patients where the cancer has spread at the time of diagnosis, the UISS predicts 3-year disease-specific survival (DSS):
| Risk Group | Clinical/Pathological Profile | 3-Year Survival (%) |
| Low | ECOG 0 and Low Grade | ~39% |
| Intermediate | ECOG 0 and High Grade OR ECOG 1+ and Low Grade | ~20% |
| High | ECOG 1+ and High Grade | ~7% |
3. Clinical Utility and Significance
The UISS is highly valued in urologic oncology for several reasons:
- Individualized Prognosis: Unlike the TNM system alone, the UISS accounts for the patient’s overall health (ECOG), which is a massive driver of survival in kidney cancer.
- Adjuvant Trial Selection: It helps clinicians identify “high-risk” patients who might benefit most from adjuvant therapies (treatments given after surgery to prevent recurrence).
- Simple Implementation: Since it relies on standard pathology reports and a quick bedside assessment of the patient’s activity level, it is easy to use in routine clinical practice.
Note: While the Fuhrman grade was a staple of the original UISS, many modern pathology reports now use the WHO/ISUP grading system. Most experts consider these systems interchangeable when applying the UISS model.
4. References
- Zisman A, et al. (2001). The UCLA Integrated Staging System: a new prognostic tool for patients with renal cell carcinoma. Cancer, 91(12), 2271-2276.
- Zisman A, et al. (2002). Improved prognostic staging of renal cell carcinoma utilizing a combined anatomic and performance status model. Analytical and Quantitative Cytology and Histology, 24(1), 35-40.
- Patard JJ, et al. (2004). Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. Journal of Clinical Oncology, 22(16), 3316-3322.
- Kim HL, et al. (2004). Using the UCLA Integrated Staging System to Predict Outcomes for Patients with Renal Cell Carcinoma. Reviews in Urology, 6(3), 107–113.
